

January 2016

**Global Strategy for Diagnosis, Management and
Prevention of COPD (2016 update)
Publications Reviewed by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) Science Committee**

The process to produce the 2016 update included a Pub Med search using search fields established by the Committee: *COPD: Abstract available, Publication date from 2014/07/01 to 2015/05/31, Humans, Clinical Trial, Randomized Controlled Trial, Meta-Analysis, Systematic Reviews, Adult: 19+ years.*

1. Airapetova NS, Nitchenko OV, Kulikova OV, Antonovich IV, Uianaeva AI. [On the usefulness of including general biologic baths in the combined therapeutic and rehabilitative treatment of the patients presenting with obstructive diseases of the respiratory organs]. *Vopr Kurortol Fizioter Lech Fiz Kult* 2014;7-12.
2. Amin S, Abrazado M, Quinn M, Storer TW, Tseng CH, Cooper CB. A controlled study of community-based exercise training in patients with moderate COPD. *BMC Pulm Med* 2014;14:125.
3. Anderson D, Najafzadeh M, Gopalan R, et al. Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics. *FASEB J* 2014;28:4563-70.
4. Armstrong EM, Wright BM, Meyer A, Watts CS, Kelley KW. The role of acclidinium bromide in the treatment of chronic obstructive pulmonary disease. *Hosp Pract (1995)* 2014;42:99-110.
5. Arora P, Kumar L, Vohra V, et al. Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. *Respir Med* 2014;108:992-8.
6. Asai M, Tanaka T, Kozu R, Kitagawa C, Tabusadani M, Senjyu H. Effect of a chronic obstructive pulmonary disease (COPD) intervention on COPD awareness in a regional city in Japan. *Intern Med* 2015;54:163-9.
7. Banga A, Gildea T, Rajeswaran J, Rokadia H, Blackstone EH, Stoller JK. The natural history of lung function after lung transplantation for alpha(1)-antitrypsin deficiency. *Am J Respir Crit Care Med* 2014;190:274-81.
8. Baria MR, Shahgholi L, Sorenson EJ, et al. B-mode ultrasound assessment of diaphragm structure and function in patients with COPD. *Chest* 2014;146:680-5.
9. Baxter M, Eltom S, Dekkak B, et al. Role of transient receptor potential and pannexin channels in cigarette smoke-triggered ATP release in the lung. *Thorax* 2014;69:1080-9.
10. Beekman E, Mesters I, Gosselink R, et al. The first reference equations for the 6-minute walk distance over a 10 m course. *Thorax* 2014;69:867-8.
11. Behrens G, Matthews CE, Moore SC, Hollenbeck AR, Leitzmann MF. Body size and physical activity in relation to incidence of chronic obstructive pulmonary disease. *CMAJ* 2014;186:E457-69.
12. Bendixen HJ, Waehrens EE, Wilcke JT, Sorensen LV. Self-reported quality of

ADL task performance among patients with COPD exacerbations. *Scand J Occup Ther* 2014;21:313-20.

13. Berenson CS, Kruzel RL, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. *Thorax* 2014;69:811-8.
14. Berkhof FF, Hesselink AM, Vaessen DL, Uil SM, Kerstjens HA, van den Berg JW. The effect of an outpatient care on-demand-system on health status and costs in patients with COPD. A randomized trial. *Respir Med* 2014;108:1163-70.
15. Bhatt SP, Sieren JC, Newell JD, Jr., Comellas AP, Hoffman EA. Disproportionate contribution of right middle lobe to emphysema and gas trapping on computed tomography. *PLoS One* 2014;9:e102807.
16. Biggerstaff M, Jhung MA, Reed C, Fry AM, Balluz L, Finelli L. Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010-2011 influenza season-United States. *J Infect Dis* 2014;210:535-44.
17. Blakeley C, Blakemore A, Hunter C, Guthrie E, Tomenson B, Dickens C. Does anxiety predict the use of urgent care by people with long term conditions? A systematic review with meta-analysis. *J Psychosom Res* 2014;77:232-9.
18. Borel JC, Pepin JL, Pison C, et al. Long-term adherence with non-invasive ventilation improves prognosis in obese COPD patients. *Respirology* 2014;19:857-65.
19. Bowler RP, Kim V, Regan E, et al. Prediction of acute respiratory disease in current and former smokers with and without COPD. *Chest* 2014;146:941-50.
20. Brockwell C, Ampikaipakan S, Sexton DW, et al. Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2014;9:715-21.
21. Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. *Thorax* 2015;70:311-9.
22. Busch AM, Scott-Sheldon LA, Pierce J, et al. Depressed mood predicts pulmonary rehabilitation completion among women, but not men. *Respir Med* 2014;108:1007-13.
23. Cai J, Chen R, Wang W, Xu X, Ha S, Kan H. Does ambient CO have protective effect for COPD patient? *Environ Res* 2015;136:21-6.
24. Carolan BJ, Hughes G, Morrow J, et al. The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. *Respir Res* 2014;15:127.
25. Chang C, Zhu H, Shen N, Han X, Chen Y, He B. Utility of the combination of serum highly-sensitive C-reactive protein level at discharge and a risk index in predicting readmission for acute exacerbation of COPD. *J Bras Pneumol* 2014;40:495-503.
26. Chatila WM, Criner GJ, Hancock WW, et al. Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic obstructive pulmonary disease compared to unaffected smokers. *Clin Exp Immunol* 2014;177:341-52.
27. Chen C, Deng Y, Chen H, et al. Decreased concentration of IL-35 in plasma of

- patients with asthma and COPD. *Asian Pac J Allergy Immunol* 2014;32:211-7.
28. Chevalier-Bidaud B, Gillet-Juvin K, Callens E, et al. Non specific pattern of lung function in a respiratory physiology unit: causes and prevalence: results of an observational cross-sectional and longitudinal study. *BMC Pulm Med* 2014;14:148.
 29. Chong SG, Kent BD, Fitzgerald S, McDonnell TJ. Pulmonary non-tuberculous mycobacteria in a general respiratory population. *Ir Med J* 2014;107:207-9.
 30. Choo JY, Lee KY, Shin C, et al. Quantitative analysis of lungs and airways with CT in subjects with the chronic obstructive pulmonary disease (COPD) candidate FAM13A gene: case control study for CT quantification in COPD risk gene. *J Comput Assist Tomogr* 2014;38:597-603.
 31. Choro P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD--an assessment of inhaler technique and patient preferences. *Respir Med* 2014;108:968-75.
 32. Chou CY, Wang SM, Liang CC, et al. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. *Medicine (Baltimore)* 2014;93:e174.
 33. Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH. Characteristics and self-rated health of overlap syndrome. *Int J Chron Obstruct Pulmon Dis* 2014;9:795-804.
 34. Collins BF, Ramenofsky D, Au DH, Ma J, Uman JE, Feemster LC. The association of weight with the detection of airflow obstruction and inhaled treatment among patients with a clinical diagnosis of COPD. *Chest* 2014;146:1513-20.
 35. Cosio BG, Shafiek H, Fiorentino F, et al. Structure-function relationship in COPD revisited: an in vivo microscopy view. *Thorax* 2014;69:724-30.
 36. Covey MK, Collins EG, Reynertson SI, Dilling DF. Resistance training as a preconditioning strategy for enhancing aerobic exercise training outcomes in COPD. *Respir Med* 2014;108:1141-52.
 37. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest* 2015;147:894-942.
 38. Cunningham TJ, Ford ES, Croft JB, Merrick MT, Rolle IV, Giles WH. Sex-specific relationships between adverse childhood experiences and chronic obstructive pulmonary disease in five states. *Int J Chron Obstruct Pulmon Dis* 2014;9:1033-42.
 39. Daffa NI, Tighe PJ, Corne JM, Fairclough LC, Todd I. Natural and disease-specific autoantibodies in chronic obstructive pulmonary disease. *Clin Exp Immunol* 2015;180:155-63.
 40. Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. *J Aerosol Med Pulm Drug Deliv* 2014;27:279-89.
 41. Danilack VA, Stolzmann KL, Gagnon DR, et al. Associations with chest illness and mortality in chronic spinal cord injury. *J Spinal Cord Med* 2014;37:662-9.
 42. de Sousa Pinto JM, Martin-Nogueras AM, Calvo-Arenillas JI, Ramos-Gonzalez J. Clinical benefits of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil Prev* 2014;34:355-9.
 43. de Torres JP, Casanova C, Marin JM, et al. Prognostic evaluation of COPD

patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. *Thorax* 2014;69:799-804.

44. de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. *Am J Respir Crit Care Med* 2015;191:285-91.

45. Demeyer H, Burtin C, Van Remoortel H, et al. Standardizing the analysis of physical activity in patients with COPD following a pulmonary rehabilitation program. *Chest* 2014;146:318-27.

46. Diaz AA, Zhou L, Young TP, et al. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. *Acad Radiol* 2014;21:1255-61.

47. Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. *Chest* 2014;146:1531-42.

48. Donohue JF, Herje N, Crater G, Rickard K. Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study. *Int J Chron Obstruct Pulmon Dis* 2014;9:745-51.

49. Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. *Respir Res* 2014;15:78.

50. Dransfield MT, Feldman G, Korenblat P, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. *Respir Med* 2014;108:1171-9.

51. Du YJ, Yang CJ, Li B, et al. Association of pro-inflammatory cytokines, cortisol and depression in patients with chronic obstructive pulmonary disease. *Psychoneuroendocrinology* 2014;46:141-52.

52. Echave-Sustaeta JM, Comeche Casanova L, Cosio BG, Soler-Cataluna JJ, Garcia-Lujan R, Ribera X. Comorbidity in chronic obstructive pulmonary disease. Related to disease severity? *Int J Chron Obstruct Pulmon Dis* 2014;9:1307-14.

53. Eckerblad J, Todt K, Jakobsson P, et al. Symptom burden in stable COPD patients with moderate or severe airflow limitation. *Heart Lung* 2014;43:351-7.

54. Evans RA, Kaplovitch E, Beauchamp MK, et al. Is quadriceps endurance reduced in COPD?: a systematic review. *Chest* 2015;147:673-84.

55. Fahim A, Kastelik JA. Palliative care understanding and end-of-life decisions in chronic obstructive pulmonary disease. *Clin Respir J* 2014;8:312-20.

56. Fisher KA, Stefan MS, Darling C, Lessard D, Goldberg RJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. *Chest* 2015;147:637-45.

57. Frei A, Muggensturm P, Putcha N, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. *J Clin Epidemiol* 2014;67:904-11.

58. Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in

- older adults with chronic obstructive pulmonary disease. *JAMA* 2014;312:1114-21.
59. Gohy ST, Detry BR, Lecocq M, et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-beta. *Am J Respir Crit Care Med* 2014;190:509-21.
 60. Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. *BMC Pulm Med* 2014;14:163.
 61. Gupta RP, Perez-Padilla R, Marks G, Vollmer W, Menezes A, Burney P. Summarising published results from spirometric surveys of COPD: the problem of inconsistent definitions. *Int J Tuberc Lung Dis* 2014;18:998-1003.
 62. Harrison SL, Janaudis-Ferreira T, Brooks D, Desveaux L, Goldstein RS. Self-management following an acute exacerbation of COPD: a systematic review. *Chest* 2015;147:646-61.
 63. He L, Zhang W, Zhang J, et al. Diaphragmatic motion studied by M-mode ultrasonography in combined pulmonary fibrosis and emphysema. *Lung* 2014;192:553-61.
 64. Hersh CP, Make BJ, Lynch DA, et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. *BMC Pulm Med* 2014;14:164.
 65. Hoffman EA, Ahmed FS, Baumhauer H, et al. Variation in the percent of emphysema-like lung in a healthy, nonsmoking multiethnic sample. The MESA lung study. *Ann Am Thorac Soc* 2014;11:898-907.
 66. Hoffmann J, Wilhelm J, Marsh LM, et al. Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. *Am J Respir Crit Care Med* 2014;190:98-111.
 67. Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. *Thorax* 2014;69:1021-6.
 68. Huang B, Yang Y, Zhu J, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. *J Am Med Dir Assoc* 2014;15:576-81.
 69. Incorvaia C, Russo A, Foresi A, et al. Effects of pulmonary rehabilitation on lung function in chronic obstructive pulmonary disease: the FIRST study. *Eur J Phys Rehabil Med* 2014;50:419-26.
 70. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. *Thorax* 2015;70:33-40.
 71. Ito K, Kohzuki M, Takahashi T, Ebihara S. Improvement in taste sensitivity following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. *J Rehabil Med* 2014;46:932-6.
 72. Jacome C, Cruz J, Gabriel R, Figueiredo D, Marques A. Functional balance in older adults with chronic obstructive pulmonary disease. *J Aging Phys Act* 2014;22:357-63.

73. Jian ZH, Lung CC, Huang JY, et al. The coexistence of common pulmonary diseases on the histologic type of lung cancer in both genders in Taiwan: a STROBE-compliant article. *Medicine (Baltimore)* 2014;93:e127.
74. Jordan RE, Adab P, Jowett S, et al. TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. *BMC Pulm Med* 2014;14:157.
75. Kalathil SG, Lugade AA, Pradhan V, et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2014;190:40-50.
76. Kariisa M, Foraker R, Pennell M, et al. Short- and long-term effects of ambient ozone and fine particulate matter on the respiratory health of chronic obstructive pulmonary disease subjects. *Arch Environ Occup Health* 2015;70:56-62.
77. Karpman C, DePew ZS, LeBrasseur NK, Novotny PJ, Benzo RP. Determinants of gait speed in COPD. *Chest* 2014;146:104-10.
78. Kawut SM, Poor HD, Parikh MA, et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. *J Am Coll Cardiol* 2014;64:2000-9.
79. Kim V, Desai P, Newell JD, et al. Airway wall thickness is increased in COPD patients with bronchodilator responsiveness. *Respir Res* 2014;15:84.
80. Kim WJ, Lim MN, Hong Y, et al. Association of lung function genes with chronic obstructive pulmonary disease. *Lung* 2014;192:473-80.
81. Kirby M, Pike D, Coxson HO, McCormack DG, Parraga G. Hyperpolarized (³He) ventilation defects used to predict pulmonary exacerbations in mild to moderate chronic obstructive pulmonary disease. *Radiology* 2014;273:887-96.
82. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. *Int J Chron Obstruct Pulmon Dis* 2014;9:697-714.
83. Kon SS, Dilaver D, Mittal M, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. *Thorax* 2014;69:793-8.
84. Konecny T, Park JY, Somers KR, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. *Am J Cardiol* 2014;114:272-7.
85. Kruis AL, Boland MR, Assendelft WJ, et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. *BMJ* 2014;349:g5392.
86. Lamontagne M, Timens W, Hao K, et al. Genetic regulation of gene expression in the lung identifies CST3 and CD22 as potential causal genes for airflow obstruction. *Thorax* 2014;69:997-1004.
87. Laveneziana P, Webb KA, Wadell K, Neder JA, O'Donnell DE. Does expiratory muscle activity influence dynamic hyperinflation and exertional dyspnea in COPD? *Respir Physiol Neurobiol* 2014;199:24-33.
88. Lazar Z, Bikov A, Martinovszky F, Galffy G, Losonczy G, Horvath I. Exhaled breath temperature in patients with stable and exacerbated COPD. *J Breath Res*

2014;8:046002.

89. Lee JH, Cho MH, Hersh CP, et al. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2015;52:365-76.
90. Lee JH, McDonald ML, Cho MH, et al. DNAH5 is associated with total lung capacity in chronic obstructive pulmonary disease. *Respir Res* 2014;15:97.
91. Li CI, Li TC, Liu CS, et al. Extreme values of hemoglobin a1c are associated with increased risks of chronic obstructive pulmonary disease in patients with type 2 diabetes: a competing risk analysis in national cohort of Taiwan diabetes study. *Medicine (Baltimore)* 2015;94:e367.
92. Lisspers K, Johansson G, Jansson C, et al. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. *Respir Med* 2014;108:1345-54.
93. Maldonado D, Gonzalez-Garcia M, Barrero M, Jaramillo C, Casas A. Exercise endurance in chronic obstructive pulmonary disease patients at an altitude of 2640 meters breathing air and oxygen (FIO₂ 28% and 35%): a randomized crossover trial. *COPD* 2014;11:401-6.
94. Manca S, Rodriguez E, Huerta A, et al. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. *COPD* 2014;11:480-8.
95. Marques A, Jacome C, Cruz J, Gabriel R, Brooks D, Figueiredo D. Family-based psychosocial support and education as part of pulmonary rehabilitation in COPD: a randomized controlled trial. *Chest* 2015;147:662-72.
96. Masala S, Magrini A, Taglieri A, et al. Chronic obstructive pulmonary disease (COPD) patients with osteoporotic vertebral compression fractures (OVCFs): improvement of pulmonary function after percutaneous vertebroplasty (VTP). *Eur Radiol* 2014;24:1577-85.
97. Maspero J, Cherrez I, Doherty DE, et al. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. *Respir Med* 2014;108:1355-62.
98. Matej R, Vasakova M, Kukal J, Sterclova M, Olejar T. Higher TGF-beta with lower CD124 and TSLP, but no difference in PAR-2 expression in bronchial biopsy of bronchial asthma patients in comparison with COPD patients. *Appl Immunohistochem Mol Morphol* 2014;22:543-9.
99. McDonald ML, Cho MH, Sorheim IC, et al. Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2014;51:678-87.
100. McDonnell LM, Hogg L, McDonnell L, White P. Pulmonary rehabilitation and sleep quality: a before and after controlled study of patients with chronic obstructive pulmonary disease. *NPJ Prim Care Respir Med* 2014;24:14028.
101. McNamara RJ, McKeough ZJ, McKenzie DK, Alison JA. Physical comorbidities affect physical activity in chronic obstructive pulmonary disease: a prospective cohort study. *Respirology* 2014;19:866-72.
102. Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-

- oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2014;134:314-22.
103. Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis* 2014;33:1101-11.
104. Mineshita M, Shikama Y, Nakajima H, et al. The application of impulse oscillation system for the evaluation of treatment effects in patients with COPD. *Respir Physiol Neurobiol* 2014;202:1-5.
105. Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. *Medicine (Baltimore)* 2014;93:e76.
106. Miravittles M, Huerta A, Fernandez-Villar JA, et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. *Health Qual Life Outcomes* 2014;12:120.
107. Mohan D, Gale NS, McEniery CM, et al. Evaluating the role of inflammation in chronic airways disease: the ERICA study. *COPD* 2014;11:552-9.
108. Moriyama M, Takeshita Y, Haruta Y, Hattori N, Ezenwaka CE. Effects of a 6-month nurse-led self-management program on comprehensive pulmonary rehabilitation for patients with COPD receiving home oxygen therapy. *Rehabil Nurs* 2015;40:40-51.
109. O'Hare PE, Ayres JF, O'Rourke RL, et al. Coronary artery calcification on computed tomography correlates with mortality in chronic obstructive pulmonary disease. *J Comput Assist Tomogr* 2014;38:753-9.
110. Oh CM, Oh IH, Lee JK, et al. Blood cadmium levels are associated with a decline in lung function in males. *Environ Res* 2014;132:119-25.
111. Ohar JA, Crater GD, Emmett A, et al. Fluticasone propionate/salmeterol 250/50 mug versus salmeterol 50 mug after chronic obstructive pulmonary disease exacerbation. *Respir Res* 2014;15:105.
112. Ohayon MM. Chronic Obstructive Pulmonary Disease and its association with sleep and mental disorders in the general population. *J Psychiatr Res* 2014;54:79-84.
113. Ongel EA, Karakurt Z, Salturk C, et al. How do COPD comorbidities affect ICU outcomes? *Int J Chron Obstruct Pulmon Dis* 2014;9:1187-96.
114. Papaporfyriou A, Loukides S, Kostikas K, et al. Increased levels of osteopontin in sputum supernatant in patients with COPD. *Chest* 2014;146:951-8.
115. Pedone C, Scarlata S, Forastiere F, Bellia V, Antonelli Incalzi R. BODE index or geriatric multidimensional assessment for the prediction of very-long-term mortality in elderly patients with chronic obstructive pulmonary disease? a prospective cohort study. *Age Ageing* 2014;43:553-8.
116. Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. *Chest* 2014;146:1521-30.
117. Postolache P, Nemes RM, Cojocaru DC. Progressive dyspnea--comprehensive evaluation of a common symptom. *Rev Med Chir Soc Med Nat Iasi* 2014;118:649-53.
118. Prieto-Centurion V, Rolle AJ, Au DH, et al. Multicenter study comparing case definitions used to identify patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2014;190:989-95.

119. Putcha N, Drummond MB, Connett JE, et al. Chronic productive cough is associated with death in smokers with early COPD. *COPD* 2014;11:451-8.
120. Quinn D, Seale JP, Reisner C, et al. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. *Respir Med* 2014;108:1327-35.
121. Rahimi-Rad MH, Rahimi P, Rahimi B, Gholamnaghad M. Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension. *Pneumologia* 2014;63:164-6.
122. Ramirez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. *Am J Respir Crit Care Med* 2014;190:996-1002.
123. Ramlal SK, Visser FJ, Hop WC, Dekhuijzen PN, Heijdra YF. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD. *Pulm Pharmacol Ther* 2014;28:158-64.
124. Rau M, Heinz W, Ullmann AJ. [Patient with COPD after allogeneic hematopoietic stem cell transplantation with cough and subfebrile temperature]. *Dtsch Med Wochenschr* 2014;139:2239-41.
125. Rennard S, Fogarty C, Reisner C, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. *BMC Pulm Med* 2014;14:118.
126. Roche N, Chavaillon JM, Maurer C, Zureik M, Piquet J. A clinical in-hospital prognostic score for acute exacerbations of COPD. *Respir Res* 2014;15:99.
127. Rossi A, Guerriero M, Corrado A, Group OAS. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). *Respir Res* 2014;15:77.
128. Rossini M, Viapiana O, Adami S, et al. Medication use before and after hip fracture: a population-based cohort and case-control study. *Drugs Aging* 2014;31:547-53.
129. Santos SR, Lizzi ES, Vianna EO. Characteristics of undiagnosed COPD in a senior community center. *Int J Chron Obstruct Pulmon Dis* 2014;9:1155-61.
130. Sasaki T, Takahashi K, Takada N, Ohsaki Y. Ratios of peripheral-to-central airway lumen area and percentage wall area as predictors of severity of chronic obstructive pulmonary disease. *AJR Am J Roentgenol* 2014;203:78-84.
131. Sato T, Arai E, Kohno T, et al. Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease. *Int J Cancer* 2014;135:319-34.
132. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. *Chest* 2014;146:924-31.
133. Shrikrishna D, Tanner RJ, Lee JY, et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. *Chest* 2014;146:932-40.
134. Shukla SD, Sohal SS, Mahmood MQ, Reid D, Muller HK, Walters EH. Airway

- epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2014;9:853-61.
135. Sicras-Mainar A, Rejas-Gutierrez J, Navarro-Artieda R, Ibanez-Nolla J. The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice. *Lung* 2014;192:505-18.
136. Siler TM, LaForce CF, Kianifard F, Williams J, Spangenthal S. Once-daily indacaterol 75 mug in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect. *Int J Chron Obstruct Pulmon Dis* 2014;9:919-25.
137. Smith BM, Hoffman EA, Rabinowitz D, et al. Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Thorax* 2014;69:987-96.
138. Sonstein L, Clark C, Seidensticker S, Zeng L, Sharma G. Improving adherence for management of acute exacerbation of chronic obstructive pulmonary disease. *Am J Med* 2014;127:1097-104.
139. Stanley SE, Chen JJ, Podlevsky JD, et al. Telomerase mutations in smokers with severe emphysema. *J Clin Invest* 2015;125:563-70.
140. Stolz D, Boersma W, Blasi F, et al. Exertional hypoxemia in stable COPD is common and predicted by circulating proadrenomedullin. *Chest* 2014;146:328-38.
141. Strang S, Farrell M, Larsson LO, et al. Experience of guilt and strategies for coping with guilt in patients with severe COPD: a qualitative interview study. *J Palliat Care* 2014;30:108-15.
142. Sun C, Zhu M, Yang Z, et al. LL-37 secreted by epithelium promotes fibroblast collagen production: a potential mechanism of small airway remodeling in chronic obstructive pulmonary disease. *Lab Invest* 2014;94:991-1002.
143. Tabak M, Brusse-Keizer M, van der Valk P, Hermens H, Vollenbroek-Hutten M. A telehealth program for self-management of COPD exacerbations and promotion of an active lifestyle: a pilot randomized controlled trial. *Int J Chron Obstruct Pulmon Dis* 2014;9:935-44.
144. Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF. The association between childhood asthma and adult chronic obstructive pulmonary disease. *Thorax* 2014;69:805-10.
145. Tanash HA, Riise GC, Ekstrom MP, Hansson L, Piitulainen E. Survival benefit of lung transplantation for chronic obstructive pulmonary disease in Sweden. *Ann Thorac Surg* 2014;98:1930-5.
146. Taniguchi N, Konno S, Isada A, et al. Association of the CAT-262C>T polymorphism with asthma in smokers and the nonemphysematous phenotype of chronic obstructive pulmonary disease. *Ann Allergy Asthma Immunol* 2014;113:31-6 e2.
147. Tao H, Luo W, Pei H, et al. [Expression and significance of hypoxia-inducible factor-1alpha in patients with chronic obstructive pulmonary disease and smokers with normal lung function]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 2014;30:852-5.
148. Tashkin DP, Li N, Kleerup EC, et al. Acute bronchodilator responses decline

- progressively over 4 years in patients with moderate to very severe COPD. *Respir Res* 2014;15:102.
149. Telenga ED, Hoffmann RF, Ruben tK, et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. *Am J Respir Crit Care Med* 2014;190:155-64.
150. Thabut G, Mornex JF, Pison C, et al. Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD. *Eur Respir J* 2014;44:78-86.
151. Tommelein E, Tollenaere K, Mehuys E, Boussey K. Pharmaceutical care for patients with COPD in Belgium and views on protocol implementation. *Int J Clin Pharm* 2014;36:697-701.
152. Tong J, Guo YM, He Y, Li GY, Chen F, Yao H. [Regulatory effects of acupuncture on exercise tolerance in patients with chronic obstructive pulmonary disease at stable phase: a randomized controlled trial]. *Zhongguo Zhen Jiu* 2014;34:846-50.
153. Tse HN, Raiteri L, Wong KY, Ng LY, Yee KS, Tseng CZ. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. *Chest* 2014;146:611-23.
154. Tsoumakidou M, Tousa S, Semitekolou M, et al. Tolerogenic signaling by pulmonary CD1c+ dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand. *J Allergy Clin Immunol* 2014;134:944-54 e8.
155. van den Bemt L, Wouters BC, Grootens J, Denis J, Poels PJ, Schermer TR. Diagnostic accuracy of pre-bronchodilator FEV1/FEV6 from microspirometry to detect airflow obstruction in primary care: a randomised cross-sectional study. *NPJ Prim Care Respir Med* 2014;24:14033.
156. van Ranst D, Stoop WA, Meijer JW, Otten HJ, van de Port IG. Reduction of exacerbation frequency in patients with COPD after participation in a comprehensive pulmonary rehabilitation program. *Int J Chron Obstruct Pulmon Dis* 2014;9:1059-67.
157. Walters JA, Tan DJ, White CJ, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2014;12:CD006897.
158. Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPD. *Respir Res* 2014;15:89.
159. Wan YF, Zheng YL, Du YP, et al. Utility of uric acid as a risk marker of extubation success in chronic obstructive pulmonary disease. *Clin Lab* 2015;61:337-44.
160. Wang CH, Chou PC, Joa WC, et al. Mobile-phone-based home exercise training program decreases systemic inflammation in COPD: a pilot study. *BMC Pulm Med* 2014;14:142.
161. Wang G, Liu B, Cao Y, et al. Effects of two Chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicenter, double-blind, randomized controlled trial. *PLoS One* 2014;9:e103168.
162. Wang J, Shen N, Du Y, et al. [Preparation of metagenomic DNA from bronchoalveolar lavage fluids of patients with chronic obstructive pulmonary diseases]. *Wei Sheng Wu Xue Bao* 2014;54:943-9.
163. Wang M, Li J, Li S, Xie Y. Effects of comprehensive therapy based on traditional Chinese medicine patterns on older patients with chronic obstructive pulmonary

disease: a subgroup analysis from a four-center, randomized, controlled study. *Front Med* 2014;8:368-75.

164. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study. *BMC Pulm Med* 2014;14:158.

165. Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. *Respir Med* 2014;108:1153-62.

166. Whyatt D, Tenneti R, Marsh J, et al. The ecological fallacy of the role of age in chronic disease and hospital demand. *Med Care* 2014;52:891-900.

167. Wong TS, Xiang YT, Tsoh J, et al. Depressive disorders in older patients with chronic obstructive pulmonary disease (COPD) in Hong Kong: a controlled study. *Aging Ment Health* 2014;18:588-92.

168. Xu JH, Xu B, Deng YQ. [Efficacy on chronic obstructive pulmonary disease at stable stage treated with cutting method and western medication]. *Zhongguo Zhen Jiu* 2014;34:951-5.

169. Yanagawa N, Kawata N, Matsuura Y, et al. Effect of threshold on the correlation between airflow obstruction and low attenuation volume in smokers assessed by inspiratory and expiratory MDCT. *Acta Radiol* 2015;56:438-46.

170. Yang DH, Tu CC, Wang SC, Wei CC, Cheng YW. Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. *Rheumatol Int* 2014;34:971-7.

171. Yi SW, Hong JS, Ohrr H, Yi JJ. Agent Orange exposure and disease prevalence in Korean Vietnam veterans: the Korean veterans health study. *Environ Res* 2014;133:56-65.

172. Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. *Drugs Aging* 2014;31:483-92.

173. Yu T, Fain K, Boyd CM, et al. Benefits and harms of roflumilast in moderate to severe COPD. *Thorax* 2014;69:616-22.

174. Yu T, Fain K, Boyd CM, et al. Benefits and harms of roflumilast in moderate to severe COPD. *Thorax* 2014;69:616-22.

175. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double-blind, active-controlled studies. *Int J Chron Obstruct Pulmon Dis* 2014;9:1133-44.